Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs)
could revolutionise biomedicine. Global burden of heart failure will soon reach USD
$90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in
hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differentiation have
improved patient care, progressed drugs to clinic and opened a new era in safety
pharmacology. Nevertheless, predictive cardiotoxicity using hPSC-CMs contrasts from
failure to almost total success. Since this likely relates to cell immaturity,
efforts are underway to use biochemical and biophysical cues to improve many of the
~ 30 structural and functional properties of hPSC-CMs towards
those seen in adult CMs. Other developments needed for widespread hPSC-CM utility
include subtype specification, cost reduction of large scale differentiation and
elimination of the phenotyping bottleneck. This review will consider these factors in
the evolution of hPSC-CM technologies, as well as their integration into high content
industrial platforms that assess structure, mitochondrial function,
electrophysiology, calcium transients and contractility. This article is part of a
Special Issue entitled: Cardiomyocyte Biology: Integration of Developmental and
Environmental Cues in the Heart edited by Marcus Schaub and Hughes
Abriel.
The development of long-term human organotypic liver-on-a-chip models for successful prediction of toxic response is one of the most important and urgent goals of the NIH/DARPA’s initiative to replicate and replace chronic and acute drug testing in animals. For this purpose we developed a microfluidic chip that consists of two microfluidic chambers separated by a porous membrane. The aim of this communication is to demonstrate the recapitulation of a liver sinusoid-on-a-chip using human cells only for a period of 28 days. Using a step-by-step method for building a 3D microtissue on-a-chip, we demonstrate that an organotypic in vitro model that reassembles the liver sinusoid microarchitecture can be maintained successfully for a period of 28 days. In addition, higher albumin synthesis (synthetic), urea excretion (detoxification) was observed under flow compared to static cultures. This human liver-on-a-chip should be further evaluated in drug-related studies.
This field is still at an early stage and major challenges need to be addressed prior to the embracement of these technologies by the pharmaceutical industry. To produce predictive drug screening platforms, several organs have to be integrated into a single microfluidic system representative of a humanoid. The routine production of metabolic biomarkers of the organ constructs, as well as their physical environment, have to be monitored prior to and during the delivery of compounds of interest to be able to translate the findings into useful discoveries.
Bone-implant material development is proceeding at a high pace, and has shifted from straightforward biomaterial testing to more advanced cell-targeted approaches for surface modification and design.It has been long known that cells can recognize and respond to topographical features by changing their morphology and behavior. The progress in surface analytical devices, as well as in techniques for production of topographical features on the nanometer scale allow for the characterization of natural tissues and the reproduction of biomimetic nanofeatures in material surfaces. In this review some of the most common surface-characterization and surface-manufacturing techniques will be addressed and results from in vitro and in vivo studies will be presented. Knowledge on biomaterial nanotopography can be exploited for active stimulation and control of cellular behavior like attachment, migration, spreading, gene expression, proliferation, differentiation and secretion of matrix components.
To evaluate drug and metabolite efficacy on a target organ, it is essential to include metabolic function of hepatocytes, and to evaluate metabolite influence on both hepatocytes and the target of interest. Herein, we have developed a two-chamber microfabricated device separated by a membrane enabling communication between hepatocytes and cancer cells. The microscale environment created enables cell co-culture in a low media-to-cell ratio leading to higher metabolite formation and rapid accumulation, which is lost in traditional plate cultures or other interconnected models due to higher culture volumes. We demonstrate the efficacy of this system by metabolism of tegafur by hepatocytes resulting in cancer cell toxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.